Philips Respironics DreamStation BiPAP S/T and AVAPS

The Philips DreamStation BiPAP S/T DreamStation BiPAP and AVAPS (HCINX1130T19 ) is an advanced noninvasive form of ventilation. It combines features of both volume-controlled and pressure-controlled ventilation, making it suitable for patients with chronic respiratory conditions like COPD, neuromuscular disorders, or obesity hypoventilation syndrome. The BiPAP S/T model offers multiple therapy modes—including CPAP, spontaneous (S), and spontaneous/timed (S/T)—with a backup rate to ensure consistent breathing support. Meanwhile, the AVAPS model builds on these features by incorporating Average Volume Assured Pressure Support, which automatically adjusts pressure to maintain a target tidal volume throughout the night. Both devices are part of the DreamStation platform, known for its sleek design, intuitive interface, and connectivity with remote monitoring systems, making them ideal for long-term home ventilation and personalized respiratory care.

DreamStation devices were marketed globally through Philips Respironics’ clinical and home-health channels and were widely used in North America, Europe, and other regions with established home respiratory therapy infrastructure. The devices targeted patients requiring noninvasive ventilatory support over nights or for chronic conditions, including those with COPD, neuromuscular disease, central or mixed sleep-disordered breathing, and obesity hypoventilation syndrome, as well as clinicians and durable medical equipment providers who manage home ventilation programs. Retail and reimbursed pricing varied by region, configuration, and payer arrangements; typical out-of-pocket or insured costs depended on local reimbursement, supplier fees, and whether the device was provided as durable medical equipment, so a single global street price is not consistently documented in public sources.

Philips Respironics issued large-scale voluntary field safety notices and recall notifications beginning in 2021 related to polyester-based polyurethane (PE-PUR) sound-abatement foam used in a range of their sleep and respiratory devices, including DreamStation family models. This program led to manufacturer-led remediation options such as repair, replacement, buyback credits, and loaner programs and prompted global registration and patient communications from Philips. The U.S. Food and Drug Administration classified related actions for DreamStation ASV, ST, AVAPS and allied models as Class I recalls, reflecting the highest level of recall severity. Clinical guidance associated with these notices recommended that patients and clinicians perform individualized risk/benefit analyses before discontinuing therapy and follow Philips’ remediation instructions. Reported failure modes and user complaints tied to the recall centered on foam degradation producing particulate matter and off-gassing that could, over time, compromise device safety or cause irritation; Philips’ remediation documents and technical advisories address inspection, repair, and replacement workflows.

Prior to the 2021 corrective actions, DreamStation BiPAP models received praise for ease of use, compact design, and connectivity that enabled remote monitoring and data download by clinicians. Common consumer feedback noted effective symptom relief for appropriate patients and favorable ergonomics for home use. Post-notice, user sentiment and clinical guidance shifted toward concern and focus on remediation and replacement logistics. Technical forums and service literature identify components that can require maintenance or replacement over long-term use such as the humidifier chamber, air filters, and patient circuit tubing. The DreamStation family followed earlier Respironics platforms and sat alongside product lines such as System One and Trilogy in Philips’ portfolio; the S/T and AVAPS models occupy the niche for non-life-supporting, long-term home bilevel ventilation with advanced algorithms for targeted ventilation, distinguishing them from simpler CPAP-only or strictly pressure-limited bilevel units.

The Philips Respironics DreamStation BiPAP S/T and AVAPS (HCINX1130T19) are identifiable by their sleek, rectangular design with a front-facing color LCD screen and intuitive control dial. Both models belong to the DreamStation line, which features a distinctive white-and-blue casing and modular components, including a detachable humidifier. The BiPAP S/T is marked by its support for spontaneous and timed breathing modes, while the AVAPS model includes additional functionality for Average Volume Assured Pressure Support, often labeled on the device or packaging. Serial numbers and model identifiers are typically located on the underside or back of the unit, and the user interface displays mode-specific settings that help distinguish between the two. These devices are commonly used in clinical and home settings with a user-friendly interface.

Therapy Features

• Therapy Modes: CPAP, S, ST, T, AVAPS, AVAPS-AE
• Pressure Range: 4–25 cm H₂O
• Target Tidal Volume: 200–1500 mL
• AVAPS Rate: 0–30 breaths per minute (BPM)
• AVAPS-AE Mode: Auto-titration with auto backup rate and airway patency management
• Digital Auto-Trak: Leak compensation and breath detection

Comfort & Hardware

• Humidification: Optional with fixed, adaptive, and heated tube options
• Water Chamber: Modular, one-piece, dishwasher-safe
• Display: Color LCD with intuitive navigation
• Dimensions: Similar to BiPAP S/T
• Weight: ~2.94 lbs (1.33 kg)
• Power Supply: 100–240 VAC, 50/60 Hz

Connectivity & Data

• Bluetooth: Compatible with DreamMapper and EncoreAnywhere
• Data Tracking: Daily usage trends and compliance feedback (SD card storage)

Philips Official Site

Philips Respironics DreamStation BiPAP S/T and AVAPS User Manual

Invasive Ventilation Setup using BiPAP AVAPS